title: [Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy in patients with chronic myeloid leukemia: two cases report and literatures review].
abstract: OBJECTIVE
  To probe the cause for triggering HBV reactivation and possible management of the chronic hepatitis B individuals received imatinib.
  
  
  METHODS
  This study presented two cases of transient hepatitis B virus (HBV) reactivation and hepatic dysfunction during oral imatinib for chronic myeloid leukemia (CML) and made a literatures review about the pathogenesis, possible prophylactic and therapeutic management of such chronic hepatitis B individuals receiving imatinib.
  
  
  RESULTS
  Two CML patients, without prior liver dysfunction but with chronic HBV infection, suffered from transient HBV reactivation occurred during oral imatinib. Both of them finally obtained good outcome following the additional oral nucleotide antiviral therapy.
  
  
  CONCLUSIONS
  It remained unclear whether imatinib induced the reactivation of HBV in patients with a latent HBV infection. From our study, all candidates receiving oral imatinib should be screened for HBsAg and anti-HBc antibodies prior to initiation of imatinib. Prophylactic antiviral therapy should be offered to HBV-infected individuals along with a close monitoring for signs of reactivation.
authors: Department of Hematology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
authors: Ya-Dan
authors: YD
authors: Wang
authors: Guo-Hui
authors: GH
authors: Cui
authors: Yong
authors: Y
authors: You
authors: Mian
authors: M
authors: Li
authors: Jia
authors: J
authors: Xia
authors: Yu
authors: Y
authors: Hu
mesh_terms: D000328:Adult; D001549:Benzamides / Q000009:adverse effects* / Q000627:therapeutic use; D006509:Hepatitis B / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000821:virology*; D008297:Male; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate